BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, Sarto P, Hansen TS, Wewer V, Bendtsen F. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008;6:1212-1217; quiz 1176. [PMID: 18848503 DOI: 10.1016/j.cgh.2008.05.010] [Cited by in Crossref: 97] [Cited by in F6Publishing: 84] [Article Influence: 6.9] [Reference Citation Analysis]
Number Citing Articles
1 Biancone L, Onali S, Petruzziello C, Calabrese E, Pallone F. Cancer and immunomodulators in inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21:674-698. [PMID: 25545375 DOI: 10.1097/mib.0000000000000243] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
2 Aloi M, Birimberg-schwartz L, Buderus S, Hojsak I, Fell JM, Bronsky J, Veereman G, Koletzko S, Shaoul R, Miele E, Turner D, Russell RK. Treatment Options and Outcomes of Pediatric IBDU Compared with Other IBD Subtypes: A Retrospective Multicenter Study from the IBD Porto Group of ESPGHAN. Inflammatory Bowel Diseases 2016;22:1378-83. [DOI: 10.1097/mib.0000000000000767] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
3 Alzafiri R, Holcroft CA, Malolepszy P, Cohen A, Szilagyi A. Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years. Clin Exp Gastroenterol 2011;4:9-17. [PMID: 21694867 DOI: 10.2147/CEG.S16168] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
4 Fausel R, Afzali A. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag 2015;11:63-73. [PMID: 25609972 DOI: 10.2147/TCRM.S55506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
5 Roccetti M, Salomoni P, Prandi C, Marfia G, Mirri S. On the interpretation of the effects of the Infliximab treatment on Crohn’s disease patients from Facebook posts: a human vs. machine comparison. Netw Model Anal Health Inform Bioinforma 2017;6. [DOI: 10.1007/s13721-017-0152-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
6 Armuzzi A, Gionchetti P, Daperno M, Danese S, Orlando A, Lia Scribano M, Vecchi M, Rizzello F; GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Dig Liver Dis. 2016;48:360-370. [PMID: 26821929 DOI: 10.1016/j.dld.2015.12.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
7 Nørgård BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OB, Kjeldsen J. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study. Aliment Pharmacol Ther 2012;35:1301-9. [PMID: 22506582 DOI: 10.1111/j.1365-2036.2012.05099.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
8 Burisch J, Lophaven S, Munkholm P, Langholz E. Surgery, cancer and mortality among patients with ulcerative colitis diagnosed 1962-1987 and followed until 2017 in a Danish population-based inception cohort. Aliment Pharmacol Ther 2021. [PMID: 34713926 DOI: 10.1111/apt.16677] [Reference Citation Analysis]
9 Oussalah A, Roblin X, Laharie D, Filippi J, Flamant M, Faure P, Phelip J, Bigard M, Peyrin-biroulet L. Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey. Alimentary Pharmacology & Therapeutics 2009;30:854-63. [DOI: 10.1111/j.1365-2036.2009.4097.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
10 de Vries HS, Van Oijen MG, de Jong DJ. Safety of Infliximab in Inflammatory Bowel Disease Needs to Be Debated. Clinical Gastroenterology and Hepatology 2009;7:603-4. [DOI: 10.1016/j.cgh.2008.12.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221-256. [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
12 Greuter T, Navarini A, Vavricka SR. Skin Manifestations of Inflammatory Bowel Disease. Clinic Rev Allerg Immunol 2017;53:413-27. [DOI: 10.1007/s12016-017-8617-4] [Cited by in Crossref: 46] [Cited by in F6Publishing: 29] [Article Influence: 9.2] [Reference Citation Analysis]
13 Laharie D, Chanteloup E, Chabrun E, Subtil C, Kowo M, El Hanafi K, DE Lédinghen V. The tolerance and efficacy of a postponed retreatment with infliximab in Crohn’s disease primary responders. Aliment Pharmacol Ther. 2009;29:1240-1248. [PMID: 19416134 DOI: 10.1111/j.1365-2036.2009.03997.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
14 Shivaji UN, Sharratt CL, Thomas T, Smith SCL, Iacucci M, Moran GW, Ghosh S, Bhala N. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2019;49:664-80. [DOI: 10.1111/apt.15097] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
15 Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study: . Inflammatory Bowel Diseases 2017;23:1174-81. [DOI: 10.1097/mib.0000000000001109] [Cited by in Crossref: 40] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
16 Travis S, Stange E, Lémann M, Øresland T, Bemelman W, Chowers Y, Colombel J, D'haens G, Ghosh S, Marteau P, Kruis W, Mortensen N, Penninckx F, Gassull M. European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn's and Colitis 2008;2:24-62. [DOI: 10.1016/j.crohns.2007.11.002] [Cited by in Crossref: 378] [Cited by in F6Publishing: 325] [Article Influence: 27.0] [Reference Citation Analysis]
17 Ramanan AV, Dick AD, Benton D, Compeyrot-Lacassagne S, Dawoud D, Hardwick B, Hickey H, Hughes D, Jones A, Woo P, Edelsten C, Beresford MW; SYCAMORE Trial Management Group. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials 2014;15:14. [PMID: 24405833 DOI: 10.1186/1745-6215-15-14] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
18 Greuter T, Bertoldo F, Rechner R, Straumann A, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Rogler G, Safroneeva E, Ali RA, Braegger C, Heyland K, Mueller P, Nydegger A, Petit L, Schibli S, Furlano RI, Spalinger J, Schäppi M, Zamora S, Froehlich F, Herzog D, Schoepfer AM, Vavricka SR. Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment. Journal of Pediatric Gastroenterology & Nutrition 2017;65:200-6. [DOI: 10.1097/mpg.0000000000001455] [Cited by in Crossref: 37] [Cited by in F6Publishing: 11] [Article Influence: 7.4] [Reference Citation Analysis]
19 Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Gilletta C, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Fumery M, Claudepierre P, Bouhnik Y, Amiot A; GETAID OBSERV-IBD study group. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther. 2018;47:485-493. [PMID: 29250803 DOI: 10.1111/apt.14419] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 11.6] [Reference Citation Analysis]
20 Katsanos KH, Torres J, Roda G, Brygo A, Delaporte E, Colombel JF. Review article: non-malignant oral manifestations in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015;42:40-60. [PMID: 25917394 DOI: 10.1111/apt.13217] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
21 Thongpooswan S, Abrudescu A. Lung sarcoidosis in etanercept treated rheumatoid arthritis patient: a case report and review of the literature. Case Rep Rheumatol 2014;2014:358567. [PMID: 25097790 DOI: 10.1155/2014/358567] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Pedersen N, Elkjaer M, Duricova D, Burisch J, Dobrzanski C, Andersen NN, Jess T, Bendtsen F, Langholz E, Leotta S. eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn’s disease. Aliment Pharmacol Ther. 2012;36:840-849. [PMID: 22971016 DOI: 10.1111/apt.12043] [Cited by in Crossref: 72] [Cited by in F6Publishing: 59] [Article Influence: 8.0] [Reference Citation Analysis]
23 Yokoyama M, Kimura MY, Ito T, Hayashizaki K, Endo Y, Wang Y, Yagi R, Nakagawa T, Kato N, Matsubara H, Nakayama T. Myosin Light Chain 9/12 Regulates the Pathogenesis of Inflammatory Bowel Disease. Front Immunol 2020;11:594297. [PMID: 33584659 DOI: 10.3389/fimmu.2020.594297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, d'Haens G, d'Hoore A, Mantzanaris G, Novacek G, Öresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, van Assche G. [Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)]. Rev Gastroenterol Mex 2015;80:32-73. [PMID: 25769217 DOI: 10.1016/j.rgmx.2014.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
25 Sofia MA, Rubin DT. The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. Dig Dis Sci 2017;62:833-42. [PMID: 28197743 DOI: 10.1007/s10620-017-4479-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
26 Madsen KG, Pottegård A, Hallas J, Kjeldsen J. Treatment Failure of TNF-α Inhibitors in Obese Patients With Inflammatory Bowel Disease—A Cohort Study. Inflammatory Bowel Diseases 2018;24:2628-33. [DOI: 10.1093/ibd/izy178] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Beigel F, Steinborn A, Schnitzler F, Tillack C, Breiteneicher S, John JM, Van Steen K, Laubender RP, Göke B, Seiderer J, Brand S, Ochsenkühn T. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf 2014;23:735-44. [PMID: 24788825 DOI: 10.1002/pds.3621] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
28 D’arcangelo G, Aloi M. Inflammatory Bowel Disease-Unclassified in Children: Diagnosis and Pharmacological Management. Pediatr Drugs 2017;19:113-20. [DOI: 10.1007/s40272-017-0213-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
29 O’neill I, Scully C. Biologics in oral medicine: principles of use and practical considerations: Biologics use and practical considerations. Oral Diseases 2012;18:525-36. [DOI: 10.1111/j.1601-0825.2012.01919.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
30 Cummings JR, Keshav S, Travis SP. Medical management of Crohn’s disease. BMJ. 2008;336:1062-1066. [PMID: 18467414 DOI: 10.1136/bmj.39547.603218.ae] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
31 de Silva S, Devlin S, Panaccione R. Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 2010;7:93-101. [PMID: 20134491 DOI: 10.1038/nrgastro.2009.221] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
32 Wauters L, Billiet T, Papamichael K, Ballet V, Joniau S, Verschueren P, Silversmit G, Van Assche G, Vermeire S, Ferrante M. Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment. Eur J Gastroenterol Hepatol 2017;29:84-90. [PMID: 27603297 DOI: 10.1097/MEG.0000000000000735] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
33 Carchman E. Crohn's Disease and the Risk of Cancer. Clin Colon Rectal Surg 2019;32:305-13. [PMID: 31275078 DOI: 10.1055/s-0039-1683923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
34 Van Assche G, Lewis JD, Lichtenstein GR, Loftus EV, Ouyang Q, Panes J, Siegel CA, Sandborn WJ, Travis SP, Colombel JF. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011;106:1594-602; quiz 1593, 1603. [PMID: 21844919 DOI: 10.1038/ajg.2011.211] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
35 Watanabe O, Ando T, Ishiguro K, Takahashi H, Ishikawa D, Miyake N, Kato T, Hibi S, Mimura S, Nakamura M. Enteral nutrition decreases hospitalization rate in patients with Crohn’s disease. J Gastroenterol Hepatol. 2010;25 Suppl 1:S134-S137. [PMID: 20586855 DOI: 10.1111/j.1440-1746.2010.06296.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
36 Lerang F, Holst R, Henriksen M, Wåhlberg H, Jelsness-jørgensen L. Antitumour necrosis factor alpha treatment in Crohn’s disease: long-term efficacy, side effects and need for surgery. Scandinavian Journal of Gastroenterology. [DOI: 10.1080/00365521.2022.2042592] [Reference Citation Analysis]
37 Nahra V, Hasbani GE, Chaaya M, Uthman I. The Use of Infliximab (Remicade®) for the Treatment of Rheumatic Diseases at a Tertiary Center in Lebanon: A 17-Year Retrospective Chart Review. Mediterr J Rheumatol 2020;31:400-5. [PMID: 33521572 DOI: 10.31138/mjr.31.4.400] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Larsen L, Drewes AM, Broberg MCH, Fallingborg J, Jacobsen BA, Jensen TB, Jess T. Changing Infliximab Prescription Patterns in Inflammatory Bowel Disease: A Population-Based Cohort Study, 1999-2014. Inflamm Bowel Dis 2018;24:433-9. [PMID: 29361095 DOI: 10.1093/ibd/izx038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
39 Bewtra M, Lewis JD. Safety Profile of IBD: Lymphoma Risks. Medical Clinics of North America 2010;94:93-113. [DOI: 10.1016/j.mcna.2009.08.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Onel KB, Onel K. Anti-tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders. Arthritis Care Res 2010;62:1024-8. [DOI: 10.1002/acr.20228] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
41 Annese V, Duricova D, Gower-rousseau C, Jess T, Langholz E. Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO. ECCOJC 2016;10:216-25. [DOI: 10.1093/ecco-jcc/jjv190] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 10.0] [Reference Citation Analysis]
42 Bandyopadhyay D, Judson MA. Emerging and potential treatment options for sarcoidosis. Expert Opinion on Orphan Drugs 2017;6:17-33. [DOI: 10.1080/21678707.2018.1411260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
43 Kamm MA, Ng SC, De Cruz P, Allen P, Hanauer SB. Practical application of anti-TNF therapy for luminal Crohn’s disease. Inflamm Bowel Dis. 2011;17:2366-2391. [PMID: 21337669 DOI: 10.1002/ibd.21655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
44 Roccetti M, Marfia G, Salomoni P, Prandi C, Zagari RM, Gningaye Kengni FL, Bazzoli F, Montagnani M. Attitudes of Crohn's Disease Patients: Infodemiology Case Study and Sentiment Analysis of Facebook and Twitter Posts. JMIR Public Health Surveill 2017;3:e51. [PMID: 28793981 DOI: 10.2196/publichealth.7004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 5.2] [Reference Citation Analysis]
45 Bewtra M, Lewis JD. Safety profile of IBD: lymphoma risks. Gastroenterol Clin North Am 2009;38:669-89. [PMID: 19913208 DOI: 10.1016/j.gtc.2009.07.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
46 Mei X, Zheng Q. Role of Cellular Biomolecules in Screening, Diagnosis and Treatment of Colorectal Cancer. CDM 2019;20:880-8. [DOI: 10.2174/1389200220666191018153428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
47 Bank S, Andersen PS, Burisch J, Pedersen N, Roug S, Galsgaard J, Turino SY, Brodersen JB, Rashid S, Rasmussen BK, Avlund S, Olesen TB, Hoffmann HJ, Nexø BA, Sode J, Vogel U, Andersen V. Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy. Pharmacogenomics J 2018;18:87-97. [PMID: 28139755 DOI: 10.1038/tpj.2016.84] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
48 Duricova D, Pedersen N, Lenicek M, Hradsky O, Bronsky J, Adamcova M, Elkjaer M, Andersen PS, Vitek L, Larsen K, Lukas M, Nevoral J, Wewer V, Munkholm P. Infliximab dependency in children with Crohn’s disease. Alimentary Pharmacology & Therapeutics 2009;29:792-9. [DOI: 10.1111/j.1365-2036.2009.03926.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
49 Bank S, Andersen PS, Burisch J, Pedersen N, Roug S, Galsgaard J, Turino SY, Brodersen JB, Rashid S, Rasmussen BK. Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogenomics J. 2014;14:526-534. [PMID: 24776844 DOI: 10.1038/tpj.2014.19] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 9.5] [Reference Citation Analysis]
50 Biancone L, Petruzziello C, Orlando A, Kohn A, Ardizzone S, Daperno M, Angelucci E, Castiglione F, D'Incà R, Zorzi F. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis. 2011;17:758-766. [PMID: 20684009 DOI: 10.1002/ibd.21416] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
51 Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:167-182. [PMID: 20227030 DOI: 10.1016/j.bpg.2010.01.002] [Cited by in Crossref: 114] [Cited by in F6Publishing: 103] [Article Influence: 9.5] [Reference Citation Analysis]
52 Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, Allez M, Duclos B, Grimaud J, Buisson A, Amiot A, Fumery M, Roblin X, Peyrin-biroulet L, Filippi J, Bouguen G, Abitbol V, Coffin B, Simon M, Laharie D, Pariente B. Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents. Clinical Gastroenterology and Hepatology 2016;14:242-250.e2. [DOI: 10.1016/j.cgh.2015.09.018] [Cited by in Crossref: 116] [Cited by in F6Publishing: 101] [Article Influence: 19.3] [Reference Citation Analysis]
53 Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991-1030. [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002] [Cited by in Crossref: 657] [Cited by in F6Publishing: 574] [Article Influence: 65.7] [Reference Citation Analysis]
54 Adamiak T, Walkiewicz-Jedrzejczak D, Fish D, Brown C, Tung J, Khan K, Faubion W, Park R, Heikenen J, Yaffee M, Rivera-Bennett MT, Wiedkamp M, Stephens M, Noel R, Nugent M, Nebel J, Simpson P, Kappelman MD, Kugathasan S. Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin: a population-based epidemiological study. Inflamm Bowel Dis. 2013;19:1218-1223. [PMID: 23528339 DOI: 10.1097/mib.0b013e318280b13e] [Cited by in Crossref: 74] [Cited by in F6Publishing: 32] [Article Influence: 8.2] [Reference Citation Analysis]
55 Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, Allez M, Duclos B, Serrero M, Buisson A, Amiot A, Fumery M, Roblin X, Peyrin-biroulet L, Filippi J, Bouguen G, Abitbol V, Coffin B, Simon M, Laharie D, Pariente B; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience. Aliment Pharmacol Ther 2018;47:588-95. [DOI: 10.1111/apt.14487] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 11.3] [Reference Citation Analysis]
56 Duricova D, Pedersen N, Lenicek M, Jakobsen C, Lukas M, Wewer V, Munkholm P. The clinical implication of drug dependency in children and adults with inflammatory bowel disease: A review. Journal of Crohn's and Colitis 2011;5:81-90. [DOI: 10.1016/j.crohns.2010.12.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
57 Zhang ZL, Fan HY, Yang MY, Zhang ZK, Liu K. Therapeutic effect of a hydroxynaphthoquinone fraction on dextran sulfate sodium-induced ulcerative colitis. World J Gastroenterol 2014; 20(41): 15310-15318 [PMID: 25386079 DOI: 10.3748/wjg.v20.i41.15310] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
58 Bewtra M, Lewis JD. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:621-31. [PMID: 20594135 DOI: 10.1586/eci.10.36] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
59 Katsanos AH, Katsanos KH. Inflammatory bowel disease and demyelination: more than just a coincidence? Expert Rev Clin Immunol 2014;10:363-73. [PMID: 24490959 DOI: 10.1586/1744666X.2014.885381] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
60 Bonovas S, Minozzi S, Lytras T, González-lorenzo M, Pecoraro V, Colombo S, Polloni I, Moja L, Cinquini M, Marino V, Goletti D, Matucci A, Tocci G, Milano GM, Scarpa R, Cantini F. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opinion on Drug Safety 2016;15:35-54. [DOI: 10.1080/14740338.2016.1238458] [Cited by in Crossref: 47] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
61 Hudesman D, Lichtiger S, Sands B. Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature. Inflamm Bowel Dis 2013;19:644-9. [PMID: 23314243 DOI: 10.1097/MIB.0b013e318280ebbd] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
62 Andersen NN, Caspersen S, Jess T, Munkholm P. Occurrence of demyelinating diseases after anti-TNFα treatment of inflammatory bowel disease: A Danish Crohn Colitis Database study. Journal of Crohn's and Colitis 2008;2:304-9. [DOI: 10.1016/j.crohns.2008.04.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
63 Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32:119-130. [PMID: 20412066 DOI: 10.1111/j.1365-2036.2010.04330.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 5.4] [Reference Citation Analysis]
64 Foersch S, Waldner MJ, Neurath MF. Colitis and Colorectal Cancer. Dig Dis 2012;30:469-76. [DOI: 10.1159/000341692] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
65 Pedersen N, Duricova D, Lenicek M, Elkjaer M, Bortlik M, Andersen PS, Vitek L, Davidsen B, Wewer V, Lukas M, Munkholm P. Infliximab dependency is related to decreased surgical rates in adult Crohn's disease patients. Eur J Gastroenterol Hepatol 2010;22:1196-203. [PMID: 20739896 DOI: 10.1097/MEG.0b013e32833dde2e] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
66 Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268-274. [PMID: 20005977 DOI: 10.1016/j.cgh.2009.11.024] [Cited by in Crossref: 189] [Cited by in F6Publishing: 175] [Article Influence: 15.8] [Reference Citation Analysis]
67 Duricova D, Pedersen N, Elkjaer M, Jensen JKS, Munkholm P. 5-Aminosalicylic acid dependency in Crohn's disease: A Danish Crohn Colitis Database study. Journal of Crohn's and Colitis 2010;4:575-81. [DOI: 10.1016/j.crohns.2010.06.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
68 Biancone L, Zuzzi S, Ranieri M, Petruzziello C, Calabrese E, Onali S, Ascolani M, Zorzi F, Condino G, Iacobelli S. Fistulizing pattern in Crohn’s disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study. J Crohns Colitis. 2012;6:578-587. [PMID: 22398047 DOI: 10.1016/j.crohns.2011.11.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
69 Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, Fiorino G, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferri F, Szymanska E, Eliakim R; ECCO. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2015;9:945-965. [PMID: 26294789 DOI: 10.1093/ecco-jcc/jjv141] [Cited by in Crossref: 189] [Cited by in F6Publishing: 170] [Article Influence: 27.0] [Reference Citation Analysis]
70 Peyrin-Biroulet L, Van Assche G, Gómez-Ulloa D, García-Álvarez L, Lara N, Black CM, Kachroo S. Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2017;15:25-36.e27. [PMID: 27392760 DOI: 10.1016/j.cgh.2016.06.025] [Cited by in Crossref: 64] [Cited by in F6Publishing: 49] [Article Influence: 10.7] [Reference Citation Analysis]
71 Foersch S, Neurath MF. Colitis-associated neoplasia: molecular basis and clinical translation. Cell Mol Life Sci. 2014;71:3523-3535. [PMID: 24830703 DOI: 10.1007/s00018-014-1636-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
72 Ehrlich AC, Patel S, Meillier A, Rothstein RD, Friedenberg FK. Chemoprevention of colorectal cancer in inflammatory bowel disease. Expert Rev Anticancer Ther 2017;17:247-55. [PMID: 28095263 DOI: 10.1080/14737140.2017.1283987] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
73 Georgakopoulou EA, Scully C. Orofacial adverse effects of biological agents. J Investig Clin Dent 2015;6:252-60. [PMID: 24850782 DOI: 10.1111/jicd.12102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
74 Rosenberg LN, Peppercorn MA. Efficacy and safety of drugs for ulcerative colitis. Expert Opinion on Drug Safety 2010;9:573-92. [DOI: 10.1517/14740331003639412] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
75 Jess T, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143:375-781.e1; quiz e13- e 14. [PMID: 22522090 DOI: 10.1053/j.gastro.2012.04.016] [Cited by in Crossref: 310] [Cited by in F6Publishing: 284] [Article Influence: 31.0] [Reference Citation Analysis]
76 Stidham RW, Higgins PD. Value of mucosal assessment and biomarkers in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4:285-291. [PMID: 20528116 DOI: 10.1586/egh.10.22] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
77 Yoneno K, Hisamatsu T, Matsuoka K, Okamoto S, Takayama T, Ichikawa R, Sujino T, Miyoshi J, Takabayashi K, Mikami Y, Mizuno S, Wada Y, Yajima T, Naganuma M, Inoue N, Iwao Y, Ogata H, Hasegawa H, Kitagawa Y, Hibi T, Kanai T. Risk and Management of Intra-Abdominal Abscess in Crohn's Disease Treated with Infliximab. Digestion 2014;89:201-8. [DOI: 10.1159/000360618] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
78 Riis A, Martinsen TC, Waldum HL, Fossmark R. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease. Scand J Gastroenterol. 2012;47:649-657. [PMID: 22472026 DOI: 10.3109/00365521.2012.672591] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
79 Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience. Journal of Crohn's and Colitis 2012;6:143-53. [DOI: 10.1016/j.crohns.2011.07.011] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 6.6] [Reference Citation Analysis]
80 Zhou YL, Xie S, Wang P, Zhang T, Lin MY, Tan JS, Zhi FC, Jiang B, Chen Y. Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China. J Dig Dis 2014;15:483-90. [PMID: 24828856 DOI: 10.1111/1751-2980.12161] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
81 Bank S, Julsgaard M, Abed OK, Burisch J, Broder Brodersen J, Pedersen NK, Gouliaev A, Ajan R, Nytoft Rasmussen D, Honore Grauslund C, Roug S, Galsgaard J, Sprogøe Høyer Finsen D, Lindby K, Sørensen J, Larsen L, Rohr Andersen M, Brandslund I, Thomassen M, Green A, Bo Bojesen A, Bek Sørensen S, Vogel U, Andersen V; Danish IBD Genetics Working Group. Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease. Aliment Pharmacol Ther 2019;49:890-903. [PMID: 30811631 DOI: 10.1111/apt.15187] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
82 Juillerat P, Sokol H, Froehlich F, Yajnik V, Beaugerie L, Lucci M, Burnand B, Macpherson AJ, Cosnes J, Korzenik JR. Factors Associated with Durable Response to Infliximab in Crohnʼs Disease 5 Years and Beyond: A Multicenter International Cohort. Inflammatory Bowel Diseases 2015;21:60-70. [DOI: 10.1097/mib.0000000000000225] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
83 Roccetti M, Prandi C, Salomoni P, Marfia G. Unleashing the true potential of social networks: confirming infliximab medical trials through Facebook posts. Netw Model Anal Health Inform Bioinforma 2016;5. [DOI: 10.1007/s13721-016-0122-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Lang M, Gasche C. Chemoprevention of colorectal cancer. Dig Dis 2015;33:58-67. [PMID: 25531498 DOI: 10.1159/000366037] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
85 Geneviève LD, Martani A, Mallet MC, Wangmo T, Elger BS. Factors influencing harmonized health data collection, sharing and linkage in Denmark and Switzerland: A systematic review. PLoS One 2019;14:e0226015. [PMID: 31830124 DOI: 10.1371/journal.pone.0226015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
86 Burisch J, Lophaven S, Langholz E, Munkholm P. The clinical course of Crohn's disease in a Danish population-based inception cohort with more than 50 years of follow-up, 1962-2017. Aliment Pharmacol Ther 2021. [PMID: 34543457 DOI: 10.1111/apt.16615] [Reference Citation Analysis]
87 Frigerio S, Lartey DA, D'Haens GR, Grootjans J. The Role of the Immune System in IBD-Associated Colorectal Cancer: From Pro to Anti-Tumorigenic Mechanisms. Int J Mol Sci 2021;22:12739. [PMID: 34884543 DOI: 10.3390/ijms222312739] [Reference Citation Analysis]
88 Con D, Van Langenberg DR, Vasudevan A. Response to: Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlate With Rate of Infection. Clin Gastroenterol Hepatol 2021;19:1077. [PMID: 33249017 DOI: 10.1016/j.cgh.2020.05.057] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
89 Greuter T, Rieder F, Kucharzik T, Peyrin-Biroulet L, Schoepfer AM, Rubin DT, Vavricka SR. Emerging treatment options for extraintestinal manifestations in IBD. Gut 2021;70:796-802. [PMID: 32847845 DOI: 10.1136/gutjnl-2020-322129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Coutzac C, Chapuis J, Poullenot F, Chabrun E, Capdepont M, Blanco P, Laharie D. Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study. J Crohns Colitis 2015;9:982-7. [PMID: 26351388 DOI: 10.1093/ecco-jcc/jjv159] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
91 Lima CCG, Queiroz NSF, Sobrado CW, Silva GLR, Nahas SC. CRITICAL ANALYSIS OF ANTI-TNF USE IN THE ERA OF NEW BIOLOGICAL AGENTS IN INFLAMMATORY BOWEL DISEASE. Arq Gastroenterol 2020;57:323-32. [PMID: 33027484 DOI: 10.1590/S0004-2803.202000000-59] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
92 Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, Constantin A, Fautrel B, Gaudin P, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Huet I, Jullien D, Launay O, Lemann M, Maillefert JF, Marolleau JP, Martinez V, Masson C, Morel J, Mouthon L, Pol S, Puéchal X, Richette P, Saraux A, Schaeverbeke T, Soubrier M, Sudre A, Tran TA, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011;78 Suppl 1:15-185. [PMID: 21703545 DOI: 10.1016/S1297-319X(11)70001-X] [Cited by in Crossref: 53] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]